Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years

Laura Cortesi, Luigi Marcheselli, Valentina Guarneri, Claudia Cirilli, Barbara Braghiroli, Angela Toss, Milena Sant, Guido Ficarra, Pier Franco Conte, Massimo Federico

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Breast cancer prognosis has improved greatly in recent years. Consequently, a thorough search for sensitive prognostic factors, able to help clinicians offer appropriate therapy, has become a priority in this area. In this study, we considered all new cases of invasive breast cancer diagnosed in the Province of Modena, Italy, between 1997 and 2007, registered by the Modena Cancer Registry. The principal endpoint of this study was relapse-free survival (RFS). A set of 11 clinic and pathological parameters was investigated. After a median follow-up of 73 months, 494 relapses were recorded. Tumor size, node status, grading, HER2 and estrogen receptor status were retained as independent factors in a multivariate analysis. Using these variables, a prognostic model was devised to identify three groups at different risk. In the training sample, the 5-year RFS rates resulted 96.0%, 82.9% and 63.7% in patients at low, intermediate and high risk, respectively (p <0.0001). In the validation sample, the 5-year RFS was 96.2%, 85.4% and 66.9%, respectively. To conclude our study demonstrates that a very simple prognostic index based on easily available clinical data may represent a useful tool for the identification of patients at different risk of relapse and may be a notable device to predict who truly benefits from medical treatment. What's new? Mammography helps catch breast tumors while they are still treatable. Identifying more sensitive prognostic factors that could be used during the course of treatment would help clinicians prevent recurrence and avoid unnecessary therapies. In this paper, the authors collected clinical, laboratory, pathological, and therapeutic information on almost 5,000 cases of operable breast cancer to find out which factors predicted successful recovery. They developed a prognostic index based on five variables that can help clinicians determine whether a patient's disease is likely to be helped by a particular drug, making it worth the toxic side effects.

Original languageEnglish
JournalInternational Journal of Cancer
Volume132
Issue number2
DOIs
Publication statusPublished - Jan 15 2013

Fingerprint

Estrogen Receptors
Breast Neoplasms
Recurrence
Neoplasms
Therapeutics
Survival
Poisons
Mammography
Italy
Registries
Multivariate Analysis
Survival Rate
Equipment and Supplies
Pharmaceutical Preparations

Keywords

  • breast cancer
  • mammographic screening
  • prognostic index

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. / Cortesi, Laura; Marcheselli, Luigi; Guarneri, Valentina; Cirilli, Claudia; Braghiroli, Barbara; Toss, Angela; Sant, Milena; Ficarra, Guido; Conte, Pier Franco; Federico, Massimo.

In: International Journal of Cancer, Vol. 132, No. 2, 15.01.2013.

Research output: Contribution to journalArticle

@article{7949b076fc914f04a2c9bd25d8047a93,
title = "Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years",
abstract = "Breast cancer prognosis has improved greatly in recent years. Consequently, a thorough search for sensitive prognostic factors, able to help clinicians offer appropriate therapy, has become a priority in this area. In this study, we considered all new cases of invasive breast cancer diagnosed in the Province of Modena, Italy, between 1997 and 2007, registered by the Modena Cancer Registry. The principal endpoint of this study was relapse-free survival (RFS). A set of 11 clinic and pathological parameters was investigated. After a median follow-up of 73 months, 494 relapses were recorded. Tumor size, node status, grading, HER2 and estrogen receptor status were retained as independent factors in a multivariate analysis. Using these variables, a prognostic model was devised to identify three groups at different risk. In the training sample, the 5-year RFS rates resulted 96.0{\%}, 82.9{\%} and 63.7{\%} in patients at low, intermediate and high risk, respectively (p <0.0001). In the validation sample, the 5-year RFS was 96.2{\%}, 85.4{\%} and 66.9{\%}, respectively. To conclude our study demonstrates that a very simple prognostic index based on easily available clinical data may represent a useful tool for the identification of patients at different risk of relapse and may be a notable device to predict who truly benefits from medical treatment. What's new? Mammography helps catch breast tumors while they are still treatable. Identifying more sensitive prognostic factors that could be used during the course of treatment would help clinicians prevent recurrence and avoid unnecessary therapies. In this paper, the authors collected clinical, laboratory, pathological, and therapeutic information on almost 5,000 cases of operable breast cancer to find out which factors predicted successful recovery. They developed a prognostic index based on five variables that can help clinicians determine whether a patient's disease is likely to be helped by a particular drug, making it worth the toxic side effects.",
keywords = "breast cancer, mammographic screening, prognostic index",
author = "Laura Cortesi and Luigi Marcheselli and Valentina Guarneri and Claudia Cirilli and Barbara Braghiroli and Angela Toss and Milena Sant and Guido Ficarra and Conte, {Pier Franco} and Massimo Federico",
year = "2013",
month = "1",
day = "15",
doi = "10.1002/ijc.27795",
language = "English",
volume = "132",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years

AU - Cortesi, Laura

AU - Marcheselli, Luigi

AU - Guarneri, Valentina

AU - Cirilli, Claudia

AU - Braghiroli, Barbara

AU - Toss, Angela

AU - Sant, Milena

AU - Ficarra, Guido

AU - Conte, Pier Franco

AU - Federico, Massimo

PY - 2013/1/15

Y1 - 2013/1/15

N2 - Breast cancer prognosis has improved greatly in recent years. Consequently, a thorough search for sensitive prognostic factors, able to help clinicians offer appropriate therapy, has become a priority in this area. In this study, we considered all new cases of invasive breast cancer diagnosed in the Province of Modena, Italy, between 1997 and 2007, registered by the Modena Cancer Registry. The principal endpoint of this study was relapse-free survival (RFS). A set of 11 clinic and pathological parameters was investigated. After a median follow-up of 73 months, 494 relapses were recorded. Tumor size, node status, grading, HER2 and estrogen receptor status were retained as independent factors in a multivariate analysis. Using these variables, a prognostic model was devised to identify three groups at different risk. In the training sample, the 5-year RFS rates resulted 96.0%, 82.9% and 63.7% in patients at low, intermediate and high risk, respectively (p <0.0001). In the validation sample, the 5-year RFS was 96.2%, 85.4% and 66.9%, respectively. To conclude our study demonstrates that a very simple prognostic index based on easily available clinical data may represent a useful tool for the identification of patients at different risk of relapse and may be a notable device to predict who truly benefits from medical treatment. What's new? Mammography helps catch breast tumors while they are still treatable. Identifying more sensitive prognostic factors that could be used during the course of treatment would help clinicians prevent recurrence and avoid unnecessary therapies. In this paper, the authors collected clinical, laboratory, pathological, and therapeutic information on almost 5,000 cases of operable breast cancer to find out which factors predicted successful recovery. They developed a prognostic index based on five variables that can help clinicians determine whether a patient's disease is likely to be helped by a particular drug, making it worth the toxic side effects.

AB - Breast cancer prognosis has improved greatly in recent years. Consequently, a thorough search for sensitive prognostic factors, able to help clinicians offer appropriate therapy, has become a priority in this area. In this study, we considered all new cases of invasive breast cancer diagnosed in the Province of Modena, Italy, between 1997 and 2007, registered by the Modena Cancer Registry. The principal endpoint of this study was relapse-free survival (RFS). A set of 11 clinic and pathological parameters was investigated. After a median follow-up of 73 months, 494 relapses were recorded. Tumor size, node status, grading, HER2 and estrogen receptor status were retained as independent factors in a multivariate analysis. Using these variables, a prognostic model was devised to identify three groups at different risk. In the training sample, the 5-year RFS rates resulted 96.0%, 82.9% and 63.7% in patients at low, intermediate and high risk, respectively (p <0.0001). In the validation sample, the 5-year RFS was 96.2%, 85.4% and 66.9%, respectively. To conclude our study demonstrates that a very simple prognostic index based on easily available clinical data may represent a useful tool for the identification of patients at different risk of relapse and may be a notable device to predict who truly benefits from medical treatment. What's new? Mammography helps catch breast tumors while they are still treatable. Identifying more sensitive prognostic factors that could be used during the course of treatment would help clinicians prevent recurrence and avoid unnecessary therapies. In this paper, the authors collected clinical, laboratory, pathological, and therapeutic information on almost 5,000 cases of operable breast cancer to find out which factors predicted successful recovery. They developed a prognostic index based on five variables that can help clinicians determine whether a patient's disease is likely to be helped by a particular drug, making it worth the toxic side effects.

KW - breast cancer

KW - mammographic screening

KW - prognostic index

UR - http://www.scopus.com/inward/record.url?scp=84869496847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869496847&partnerID=8YFLogxK

U2 - 10.1002/ijc.27795

DO - 10.1002/ijc.27795

M3 - Article

C2 - 22915138

AN - SCOPUS:84869496847

VL - 132

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -